# Lumexa Imaging Holdings, Inc.: overview LMRI · Nasdaq · CIK 2071288 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lmri.md) · [Financials](/companies/lmri/financials.md) · [Filings](/companies/lmri/filings.md) · [Insiders](/companies/lmri/insiders.md) Latest reported revenue: [$264.2m](/filings/0001193125-26-348902.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-348902). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [245](/filings/0001193125-26-219480.md) | [251](/filings/0001193125-26-348902.md) | [253](/filings/0001193125-26-219480.md) | [264](/filings/0001193125-26-348902.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [10.4%](/filings/0001193125-26-219480.md) | [11.0%](/filings/0001193125-26-348902.md) | [7.7%](/filings/0001193125-26-219480.md) | [8.7%](/filings/0001193125-26-348902.md) | | Net margin | % | [(3.1%)](/filings/0001193125-26-348902.md) | [(2.9%)](/filings/0001193125-26-348902.md) | [0.7%](/filings/0001193125-26-348902.md) | [1.0%](/filings/0001193125-26-348902.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001193125-26-219480.md) | [(0.10)](/filings/0001193125-26-348902.md) | [0.02](/filings/0001193125-26-219480.md) | [0.03](/filings/0001193125-26-348902.md) | | Free cash flow | $m | [(15.0)](/filings/0001193125-26-219480.md) | [(2.5) d](/filings/0001193125-26-348902.md) | [(2.4)](/filings/0001193125-26-219480.md) | [23.1 d](/filings/0001193125-26-348902.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lmri/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $65.2m | 5,777,574 | | Added +4,072,497 | | [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $39.0m | 3,453,723 | | Added +1,119,143 | | [Think Investments LP](/funds/1635999.md) | 2026-06-30 | $28.9m | 2,559,501 | | New +2,559,501 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $24.3m | 2,151,538 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $18.1m | 2,100,356 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.8m | 1,398,112 | | Reduced −127,571 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $13.3m | 1,154,463 | | Added +49,956 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.1m | 1,070,325 | | Added +11,839 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $9.1m | 807,428 | | Added +41,919 | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $8.9m | 789,040 | | Added +459,040 | ## Recent filings [All 71 filings](/companies/lmri/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 14:54 ET | [10-Q](/filings/0001193125-26-348902.md) | Quarterly report, period 2026-06-30 | 0001193125-26-348902 | | 2026-08-12 | 16:05 ET | [8-K](/filings/0001193125-26-346813.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-346813 | | 2026-06-30 | 17:08 ET | [8-K](/filings/0001193125-26-290788.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-290788 | | 2026-06-12 | 16:05 ET | [8-K](/filings/0001193125-26-269379.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-269379 | | 2026-05-12 | 16:15 ET | [10-Q](/filings/0001193125-26-219480.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219480 | | 2026-05-12 | 16:08 ET | [8-K](/filings/0001193125-26-219415.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-219415 | | 2026-04-28 | 16:36 ET | [DEF 14A](/filings/0001193125-26-187316.md) | Proxy statement, period 2026-06-10 | 0001193125-26-187316 | | 2026-04-09 | 17:11 ET | [8-K](/filings/0001193125-26-149837.md) | 7.01 Regulation FD disclosure | 0001193125-26-149837 | | 2026-03-30 | 17:32 ET | [10-K](/filings/0001193125-26-131907.md) | Annual report, period 2025-12-31 | 0001193125-26-131907 | | 2026-03-26 | 06:09 ET | [8-K](/filings/0001193125-26-124978.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-124978 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-131907.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/da82018d-dd0b-419a-82ef-bb52351991b7) ## About the filer - CIK: 2071288 - Tickers: LMRI - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.